Burning Rock Biotech vs Exagen
Burning Rock Biotech and Exagen are similar in size: $75.1m and $66.6m of revenue in their latest fiscal years. Exagen grew faster (19.7% against 4.7%). Burning Rock Biotech kept more of each dollar of sales as profit: a net margin of -10.3% against -30.0%.
| Latest fiscal year | Burning Rock BiotechBNR, 2025 | ExagenXGN, 2025 |
|---|---|---|
| Revenue | $75.1m | $66.6m |
| Revenue growth | 4.7% | 19.7% |
| Net income | −$7.7m | −$20.0m |
| Operating margin | — | -21.1% |
| Net margin | -10.3% | -30.0% |
| Return on equity | -9.9% | -147.8% |
| Free cash flow | −$4.7m | −$14.3m |
| Cash | $68.4m | $32.2m |
| Total debt | $243,097 | $22.9m |
| Debt to equity | — | 131.3% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 220 |
| Market value | $115m | $203m |
| Price vs our value range | — | — |
| Moat score | — | 16 (Weak) |
| Insider trades, 12 months | 8 buys, 0 sales | 1 buys, 5 sales |